Synthetic opioids are a class of compounds that are of particular concern due to their high potency and potential health impacts. With the relentless emergence of new synthetic opioid derivatives, non-targeted screening strategies are required that do not rely on the use of library spectra or reference materials. In this study, product ion searching, and Kendrick mass defect analysis were investigated for non-targeted screening of synthetic opioids. The estimated screening cut-offs for these techniques ranged between 0.05 and 0.1 ng/mL. These techniques were designed to not be reliant on a particular vendor's software, meaning that they can be applied to existing drug screening protocols, without requiring the development and validation of new analytical procedures. The efficacy of the developed techniques was tested through blind trials, with spiked samples inserted amongst authentic plasma samples, which demonstrated the usefulness of these methods for high-throughput screening. The use of a non-targeted screening workflow that contains complementary techniques can increase the likelihood of detecting compounds of interest within a sample, as well as the confidence in detections that are made.

中文翻译：

---

寻找众所周知的针头：马血浆中合成阿片类药物的非靶向筛查

合成阿片类药物是一类特别受关注的化合物，因为它们具有高效力和潜在的健康影响。随着新的合成阿片衍生物的不断出现，需要不依赖使用图书馆光谱或参考材料的非靶向筛选策略。在本研究中，对合成阿片类药物的非靶向筛选进行了产物离子搜索和 Kendrick 质量缺陷分析。这些技术的估计筛选临界值介于 0.05 和 0.1 ng/mL 之间。这些技术旨在不依赖于特定供应商的软件，这意味着它们可以应用于现有的药物筛选方案，而无需开发和验证新的分析程序。已开发技术的功效通过盲试进行测试，将加标样品插入真实的血浆样品中，这证明了这些方法对于高通量筛选的有用性。使用包含互补技术的非靶向筛选工作流程可以增加检测样品中感兴趣化合物的可能性，以及所进行检测的可信度。